The UK’s fastest-growing news and insight platform for the care sector.

Looking for something specific? Try a search…

Global Care Stories

Health and social care stories from around the world.

Discover the latest international news, inspiring frontline stories, innovation, best practice and real experiences shaping health and social care across the globe.

FDA approves groundbreaking new treatment for narcolepsy

Image for illustrative purposes only and may not depict the people, service or location featured in this article.

The US Food and Drug Administration (FDA) has approved a new treatment for narcolepsy type 1 that targets an underlying cause of the condition, marking a significant development for people living with the rare neurological disorder.

Orzeyful, also known as oveporexton, has been developed by Takeda and works by activating orexin receptors in the brain. People with narcolepsy type 1 have a deficiency of orexin, a chemical that plays an important role in regulating wakefulness and sleep. Unlike existing treatments that largely manage individual symptoms, the new drug is designed to restore orexin signalling and address the underlying deficiency associated with the condition.

The approval follows two Phase 3 trials involving 273 adults with narcolepsy type 1. Patients receiving Orzeyful demonstrated improvements in their ability to remain awake, experienced fewer episodes of cataplexy – the sudden loss of muscle control associated with narcolepsy type 1 – and reported improvements in nighttime sleep compared with those receiving a placebo.

The treatment represents a new approach to managing a condition that can have a substantial impact on everyday life. Narcolepsy type 1 can cause severe daytime sleepiness, disrupted nighttime sleep and cataplexy, with symptoms potentially affecting people’s ability to work, study, drive and carry out everyday activities.

Orzeyful will not become immediately available following FDA approval. The drug must first undergo scheduling by the US Drug Enforcement Administration, a process that can take up to 90 days.

The approval could also have wider implications for sleep medicine, with several pharmaceutical companies now developing treatments that target the orexin system for narcolepsy and other neurological and sleep-related conditions.

Medical Disclaimer: The information provided by Daily Round is for general informational and educational purposes only and should not be considered medical advice, diagnosis or treatment. Medical information can change as new evidence and guidance become available. Always seek advice from a qualified healthcare professional regarding any medical condition, symptoms, medication or treatment, and never delay seeking professional medical advice because of something you have read on Daily Round. In a medical emergency, contact the appropriate emergency service immediately.

Stay informed with the stories shaping health and social care.

Register with The Daily Round for the latest sector news, inspections & reports, wellbeing content, workforce insights, expert features and practical updates—delivered free to your inbox.

Posted by:
Mubitha Ramalani
Editorial Assistant – The Daily Round

Stay informed. Stay connected. Stay ahead.

Sign up for FREE daily news, practical insights, opportunities and wellbeing support. Complete the short form below to personalise your experience with The Daily Round.

Your Information
Your Interests
By subscribing, you agree to receive emails from The Daily Round, including news, updates and other relevant communications. Your information will be processed in accordance with our Privacy Policy and Terms of Use. You can unsubscribe at any time.

Sign up to our daily briefing

You can unsubscribe at any time. Please refer to our Policies for more information.

Stay informed. Stay connected. Stay ahead.

Sign up for FREE daily news, practical insights, opportunities and wellbeing support. Complete the short form below to personalise your experience with The Daily Round.

Your Information
Your Interests
By subscribing, you agree to receive emails from The Daily Round, including news, updates and other relevant communications. Your information will be processed in accordance with our Privacy Policy and Terms of Use. You can unsubscribe at any time.